Record mula sa primary source
Decision-gradeTopline na resulta
INmune Bio: XPro1595 umabot sa white-matter MRI endpoint sa Ph2 MINDFuL Alzheimer’s trial
Phase 2 MINDFuL trial umabot sa exploratory chi-separation MRI white-matter biomarker endpoint na may statistically significant treatment effect sa full mITT population (p=0.0028, d=0.46, n=200) at mas malakas na epekto sa inflammation-enriched subgroup (p=0.0098, d=0.59, n=100). Ang resulta ay nagpapatunay ng target engagement sa myelin at sumusuporta sa precision-medicine strategy para sa paparating na Phase 2b/3 registrational program.
Mahahalagang fact
- Na-file
- Hun 2, 2026, 08:00 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
INMBINmune Bio Inc.- Asset
- XPro1595
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- N ng buong mITT
- 200
- P-value ng buong mITT
- 0.0028
- N ng grupong pinayaman ng biomarker
- 100
- Laki ng epekto ng buong mITT
- d=0.46
- P-value ng grupong pinayaman ng biomarker
- 0.0098
- Laki ng epekto ng grupong pinayaman ng biomarker
- d=0.59
Sipi mula sa source
EX-99.1 2 ea029332501ex99-1.htm PRESS RELEASE DATED JUNE 2, 2026 Exhibit 99.1 INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program. BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company fo
Higit pa tungkol sa asset na ito
Kapansin-pansin
May 14, 2026
12:00 PM
INMBINmune Bio Inc.INmune Bio: FDA Fast Track para sa XPro sa maagang Alzheimer's